PPD (NASDAQ: PPD) is one of 35 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare PPD to related companies based on the strength of its risk, dividends, analyst recommendations, earnings, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares PPD and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
PPD $4.03 billion N/A 17.86
PPD Competitors $1.24 billion $44.58 million 9.28

PPD has higher revenue, but lower earnings than its competitors. PPD is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for PPD and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PPD 0 0 14 0 3.00
PPD Competitors 193 871 1649 80 2.58

PPD presently has a consensus price target of $32.46, suggesting a potential upside of 85.49%. As a group, “Commercial physical research” companies have a potential upside of 51.17%. Given PPD’s stronger consensus rating and higher possible upside, analysts clearly believe PPD is more favorable than its competitors.

Profitability

This table compares PPD and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PPD N/A N/A N/A
PPD Competitors -123.36% -4.32% -3.12%

Institutional and Insider Ownership

51.1% of shares of all “Commercial physical research” companies are held by institutional investors. 17.4% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

PPD beats its competitors on 8 of the 11 factors compared.

PPD Company Profile

PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company offers clinical development and laboratory services to the pharmaceutical, biotechnology, and medical device and government organizations, as well as other industry participants. It operates in two segments, Clinical Development Services and Laboratory Services. The Clinical Development Services segment provides product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The Laboratory Services segment offers bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. The company operates in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

Receive News & Ratings for PPD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PPD and related companies with MarketBeat.com's FREE daily email newsletter.